CagriSema (Semaglutide + Cagrilintide) — Evidence Review
Evidence review of semaglutide plus cagrilintide (CagriSema): what the REDEFINE and REIMAGINE trials found, what is unknown, and the risks. Not a use protocol.
What is CagriSema?
CagriSema is Novo Nordisk's name for a once-weekly combination of semaglutide, a GLP-1 receptor agonist with its own FDA labels (Wegovy, Ozempic, Rybelsus), and cagrilintide, a long-acting amylin analogue. Phase 3 results for the combination are published, but no label for CagriSema or cagrilintide appears in DailyMed or openFDA (searched 6 November 2026). This page describes the trials and their limits. It is not a protocol for use.
Three terms recur. HbA1c is a blood test of average blood glucose over the previous two to three months. An "estimand" is the specific effect a trial sets out to estimate; the "efficacy estimand" assumes treatment was taken as intended, while the "treatment-policy" estimand counts people as randomised whether or not they kept taking it. "Non-inferiority" means a trial tests whether one treatment is not worse than another by more than a margin set in advance.
What are the key facts?
- REDEFINE 1 (obesity, no diabetes). In 3,417 adults followed for 68 weeks, weight fell 20.4% on semaglutide 2.4 mg plus cagrilintide 2.4 mg and 3.0% on placebo (estimated difference -17.3 percentage points). Gastrointestinal adverse events affected 79.6% on CagriSema and 39.9% on placebo (PMID 40544433). The trial also had semaglutide-alone and cagrilintide-alone arms (302 people each), but the abstract reports only the comparison with placebo.
- REDEFINE 2 (obesity with type 2 diabetes). In 1,206 adults, weight fell 13.7% on CagriSema and 3.4% on placebo over 68 weeks. An HbA1c of 6.5% or less was reached by 73.5% on CagriSema and 15.9% on placebo. Gastrointestinal events were reported by 72.5% and 34.4% (PMID 40544432). REDEFINE 2 compared CagriSema with placebo only.
- REDEFINE 5 (Japan and Taiwan). In 331 adults, weight fell 18.4% on CagriSema and 11.9% on semaglutide 2.4 mg alone over 68 weeks (difference -6.5 percentage points); gastrointestinal disorders were reported by 53% and 51% (PMID 42009015).
- REIMAGINE 2 (type 2 diabetes, comparison with the single drugs). In 2,713 adults on metformin, with or without an SGLT2 inhibitor, HbA1c fell 1.91 percentage points on CagriSema (2.4 mg of each) and 1.75 on semaglutide 2.4 mg over 68 weeks (efficacy estimand; estimated difference -0.16, 95% CI -0.27 to -0.05). Adverse events were reported by 86.9% on CagriSema, 81.2% on semaglutide 2.4 mg, 82.2% on cagrilintide 2.4 mg and 70.5% on placebo (PMID 42251859). A published correction (Lancet Diabetes & Endocrinology 2026;14:e11) applies to this paper and could not be read; it may change figures in the abstract, including the HbA1c results quoted here, so check the paper.
- REIMAGINE 1 and 3 ran 40 weeks, not 68. In REIMAGINE 1 (189 adults, diet and exercise alone) HbA1c fell 1.8 percentage points on 2.4 mg of each and 1.5 on 1.0 mg of each against 0.1 on placebo, with weight falls of 13.8% and 11.8% against 1.4% (PMID 42251860). In REIMAGINE 3 (274 adults on basal insulin) HbA1c fell 2.33% and 2.10% against 0.66% on placebo, with no severe hypoglycaemia reported and one death, judged unrelated to treatment (a malignancy, in the 1.0 mg group) (PMID 42251856).
- Blood pressure. A secondary and post hoc analysis (an analysis done after the trial, not planned in advance) of REDEFINE 1 found systolic blood pressure fell 10.9 mm Hg on CagriSema and 2.8 mm Hg on placebo at week 68 (PMID 41328546). It is an analysis within the same trial, not a separate trial.
What did the earlier trials show?
- Cagrilintide alone (phase 2). In 706 adults with overweight or obesity, once-weekly cagrilintide 0.3 to 4.5 mg for 26 weeks lowered weight by 6.0% to 10.8%, against 3.0% on placebo and 9.0% on liraglutide 3.0 mg daily. Gastrointestinal adverse events occurred in 41% to 63% on cagrilintide and 32% on placebo, mainly nausea (20% to 47% against 18%), and administration-site reactions were also among the most frequent adverse events (PMID 34798060).
- Phase 1b with semaglutide 2.4 mg. In healthy adults with a BMI of 27 to 39.9, cagrilintide (0.16 to 4.5 mg) was given with semaglutide 2.4 mg, with both drugs co-escalated in 4-week steps over 16 weeks. The authors report that exposure to cagrilintide was proportional to dose and did not affect semaglutide exposure, and that cagrilintide's half-life was 159 to 195 hours. At week 20 weight had fallen 17.1% on cagrilintide 2.4 mg plus semaglutide 2.4 mg and 9.8% on pooled placebo plus semaglutide 2.4 mg (PMID 33894838).
- Phase 2 in type 2 diabetes. In 92 adults for 32 weeks, weight fell 15.6% on CagriSema, 5.1% on semaglutide and 8.1% on cagrilintide; HbA1c fell 2.2, 1.8 and 0.9 percentage points. The HbA1c difference from semaglutide was not significant (p=0.075) (PMID 37364590). The trial's ClinicalTrials.gov results list nausea in 9 of 31 on CagriSema, 5 of 31 on semaglutide and 4 of 30 on cagrilintide, and serious adverse events in 0, 2 and 4 participants (NCT04982575).
Has CagriSema been compared with tirzepatide?
No randomised head-to-head result has been published: on 6 November 2026 the PubMed search (CagriSema OR cagrilintide) AND tirzepatide AND Randomized Controlled Trial[pt] returned 0 records. An indirect network meta-analysis of 25 randomised trials against placebo, which states that no direct head-to-head studies had compared all the drugs, reported mean weight reductions against placebo of 17.97% for tirzepatide 15 mg, 17.84% for cagrilintide 4.5 mg plus semaglutide 2.4 mg and 17.46% for cagrilintide 2.4 mg plus semaglutide 2.4 mg, the dose pair used in the phase 3 trials (PMID 42207966). ClinicalTrials.gov (6 November 2026) lists REDEFINE 4 (NCT06131437), comparing CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg in adults with obesity, as completed with 809 participants and no results posted. Two further registered comparisons with tirzepatide in type 2 diabetes, NCT06221969 and NCT06534411, are also listed as completed with no results posted.
What does the evidence not show?
- Cardiovascular outcomes. REDEFINE 3 (NCT05669755), a trial in people with cardiovascular disease, is registered and listed as active, not recruiting, with no results posted on 6 November 2026. None of the published abstracts above reports cardiovascular events.
- Length of follow-up. The longest published trials ran 68 weeks. Weight and HbA1c after stopping treatment are not reported in the trials above.
- Wider populations. The trials enrolled adults meeting the BMI and HbA1c criteria in each abstract. They do not address use outside those groups.
- Cagrilintide on its own. Outside combination with semaglutide, cagrilintide was tested in the phase 2 dose-finding trial and in the cagrilintide 2.4 mg arms of REDEFINE 1, REIMAGINE 2 and the phase 2 diabetes trial.
What are the risks?
Not established: there is no label for cagrilintide or CagriSema from the developer or a regulator in DailyMed or openFDA (searched 6 November 2026), so no labelled contraindications, boxed warning or monitoring instructions exist to quote for them. In REDEFINE 1, REDEFINE 2 and the phase 2 cagrilintide trial, gastrointestinal adverse events were more common than with placebo, and administration-site reactions were among the most frequent events with cagrilintide alone.
Semaglutide is half of the combination, and the current Wegovy label (version 19, 18 June 2026) says the following.
- Contraindications. A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and a prior serious hypersensitivity reaction to semaglutide or any of the excipients (inactive ingredients).
- Boxed warning. "In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures." It is unknown whether it causes them, including MTC, in humans.
- Limitation of use. Concomitant use of Wegovy with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
- Acute Pancreatitis. Fatal and non-fatal haemorrhagic or necrotising pancreatitis has been observed with GLP-1 receptor agonists. If it is suspected, discontinue Wegovy and start appropriate management.
- Acute Gallbladder Disease. In adult weight-reduction trials, cholelithiasis (gallstones) was reported by 1.6% on Wegovy injection against 0.7% on placebo, and by 2.5% on Wegovy tablets against 1%; cholecystitis (gallbladder inflammation) by 0.6% against 0.2% on the injection. In patients aged 12 and over, cholelithiasis was 3.8% against 0% and cholecystitis 0.8% against 0%. The incidence was greater than on placebo even after accounting for weight loss.
- Hypoglycemia. "WEGOVY lowers blood glucose and can cause hypoglycemia." In a weight-reduction trial in adults with type 2 diabetes and a BMI of 27 or more (Study 3), hypoglycaemia (plasma glucose below 54 mg/dL) was reported in more patients on Wegovy than on placebo, including one episode of severe hypoglycaemia in a Wegovy-treated patient and none on placebo. In glycaemic-control trials the risk was increased when semaglutide was used with insulin or an insulin secretagogue such as a sulfonylurea. Use in type 1 diabetes, or added to insulin, has not been evaluated. The label says to monitor blood glucose before and during treatment in people with diabetes, and to consider reducing the dose of insulin or the insulin secretagogue when starting Wegovy.
- Acute Kidney Injury Due to Volume Depletion. Postmarketing cases, some needing haemodialysis, mostly in people whose gastrointestinal reactions led to dehydration; monitor kidney function, especially during dose initiation and escalation.
- Severe Gastrointestinal Adverse Reactions. Reported in 4.1% on Wegovy injection against 0.9% on placebo, and in 2% on Wegovy tablets against 0%. Wegovy is not recommended in people with severe gastroparesis (slow emptying of the stomach).
- Hypersensitivity Reactions. Serious reactions (anaphylaxis, angioedema) have been reported; discontinue Wegovy if they occur. The label says to use caution in a person with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist.
- Diabetic Retinopathy Complications in Patients with Type 2 Diabetes. In the 2-year trial in adults with type 2 diabetes and high cardiovascular risk, complications occurred in 3% on semaglutide against 1.8% on placebo; the absolute risk increase was larger in people with a history of diabetic retinopathy (8.2% against 5.2%) than in those without (0.7% against 0.4%). Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, and patients with a history should be monitored for progression.
- Heart Rate Increase. Mean increases of 1 to 4 beats per minute in adults; a rise of 10 to 19 beats per minute in 41% against 34% on placebo, and of 20 or more in 26% against 16%. Monitor heart rate, and discontinue Wegovy if there is a sustained increase in resting heart rate.
- Pulmonary Aspiration During General Anesthesia or Deep Sedation. Rare postmarketing cases in people who had residual gastric contents despite fasting; patients should tell their healthcare providers before any planned surgery or procedure.
- Never Share WEGOVY FlexTouch Between Patients. The pen must never be shared, even if the needle is changed, because of the risk of transmitting blood-borne pathogens.
- Other. Injection-site reactions were reported in 1.4% on Wegovy and 1% on placebo. Wegovy delays gastric emptying and can affect the absorption of oral medicines; the label says to monitor their effects, with more monitoring for those with a narrow therapeutic index.
- Pregnancy. Discontinue Wegovy in pregnant patients using it for weight reduction, and at least 2 months before a planned pregnancy because of the long half-life.
UK regulatory position
This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.
On 3 November 2026 the electronic medicines compendium (eMC) product search https://www.medicines.org.uk/emc/search?q=cagrilintide returned 0 products. eMC is not a complete register: it returns no result for Scenesse, which NICE records as having a UK marketing authorisation. The MHRA Products database was not searched.
The MHRA states: "In the UK, there are several licensed GLP-1 medicines including semaglutide (sold under the brand names Wegovy, Ozempic and Rybelsus), tirzepatide (Mounjaro) and liraglutide (sold under various brand names)." (MHRA, GOV.UK, page updated 5 February 2026)
The same MHRA page warns: "Products supplied as a powder in vials which must be mixed with a liquid prior to injection are not authorised and pose significant health risks."
Related pages
- Cagrilintide monograph
- Semaglutide monograph
- Tirzepatide vs Cagrilintide comparison
- CagriSema mechanism explainer
- GLP-1 & Incretin Research Hub
What doses have actually been studied?
For each compound: whether a study, a trial registration or a current regulatory label exists, and the figure it reports. Every row links to its source. This is a record of what was studied, not a schedule, and not a recommendation. See our responsible information policy.
Semaglutide
Has a regulatory labelSemaglutide alone is FDA-approved (Novo Nordisk) as Wegovy for weight reduction. The current Wegovy label (June 2026) starts at 0.25 mg once weekly for 4 weeks, increases in steps every 4 weeks to a maintenance dose of 1.7 mg or 2.4 mg, and allows a maximum of 7.2 mg after at least 4 weeks on 2.4 mg. Ozempic, for type 2 diabetes, has a maximum of 2 mg weekly. Semaglutide 2.4 mg alone was one arm of REDEFINE 1 and REIMAGINE 2.
| Figure in the study | Who it was studied in | Study length | Source |
|---|---|---|---|
| 1.7 mg or 2.4 mgSubcutaneous, Once weekly, as reported | Adults, weight reduction (Wegovy label, maintenance) | Not applicable (label) | DailyMed labelQuoted from the sourceThe maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly. |
| Maximum 7.2 mgSubcutaneous, Once weekly, as reported | Adults, where additional weight reduction is clinically indicated (Wegovy label) | Not applicable (label) | DailyMed labelQuoted from the sourcethe dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly. |
| 2.4 mg aloneSubcutaneous, Once weekly, as reported | Adults without diabetes with a BMI of 30 or more, or 27 or more with an obesity-related complication (REDEFINE 1, semaglutide-alone arm) (n = 302) | 68 weeks | PubMed 40544433Quoted from the sourcesemaglutide alone at a dose of 2.4 mg |
Cagrilintide
Some human studies publishedDailyMed and openFDA searches on 6 November 2026 returned no label for cagrilintide or CagriSema. Cagrilintide alone was tested in a phase 2 dose-finding trial (0.3 to 4.5 mg once weekly for 26 weeks, 706 adults, PMID 34798060) and in the cagrilintide 2.4 mg arms of REDEFINE 1, REIMAGINE 2 and the phase 2 diabetes trial. The other trials cited here gave it with semaglutide, mostly as the fixed-dose combination CagriSema. The abstracts give maintenance doses and treatment length, not the dose at each step. The phase 1b trial co-escalated both drugs in 4-week intervals over 16 weeks (PMID 33894838), and the REDEFINE 1 registry record gives a 16-week escalation period; neither the published abstracts nor that registry record give the cagrilintide dose at each step.
| Figure in the study | Who it was studied in | Study length | Source |
|---|---|---|---|
| 0.3 to 4.5 mgSubcutaneous self-injection, Once weekly, as reported | Adults with overweight or obesity without diabetes (phase 2 dose-finding, cagrilintide alone) (n = 706) | 26 weeks | PubMed 34798060Quoted from the sourceonce-weekly cagrilintide (0·3, 0·6, 1·2, 2·4, or 4·5 mg), once-daily liraglutide 3·0 mg, or volume-matched placebo |
| 0.16 to 4.5 mg, with semaglutide 2.4 mgSubcutaneous, Once weekly, as reported | Adults aged 18 to 55 with a BMI of 27 to 39.9, otherwise healthy (phase 1b) | 16 weeks of escalation, 4 weeks at the target dose, 5 weeks of follow-up | PubMed 33894838Quoted from the sourceonce-weekly subcutaneous cagrilintide (0·16, 0·30, 0·60, 1·2, 2·4, or 4·5 mg) or matched placebo, in combination with once-weekly subcutaneous semaglutide 2·4 mg |
| 2.4 mg of eachSubcutaneous, Once weekly, as reported | Adults with type 2 diabetes and a BMI of 27 or more (phase 2, CagriSema, semaglutide or cagrilintide alone) (n = 92) | 32 weeks | PubMed 37364590Quoted from the sourceonce-weekly subcutaneous CagriSema, semaglutide, or cagrilintide (all escalated to 2·4 mg) |
| 2.4 mg of eachSubcutaneous, Once weekly, as reported | Adults without diabetes with a BMI of 30 or more, or 27 or more with an obesity-related complication (REDEFINE 1) (n = 3417) | 68 weeks | PubMed 40544433Quoted from the sourcethe combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg |
| 2.4 mg of eachSubcutaneous, Once weekly, as reported | Adults with a BMI of 27 or more and type 2 diabetes (REDEFINE 2) (n = 1206) | 68 weeks | PubMed 40544432Quoted from the sourceonce-weekly cagrilintide-semaglutide (2.4 mg each) or placebo |
| 2.4 mg of each, against semaglutide 2.4 mgSubcutaneous, Once weekly, as reported | Adults in Japan and Taiwan with overweight or obesity, with or without type 2 diabetes (REDEFINE 5) (n = 331) | 68 weeks | PubMed 42009015Quoted from the sourcecagrilintide-semaglutide or semaglutide (both escalated to 2·4 mg) |
| 2.4 mg of each or 1.0 mg of eachSubcutaneous, Once weekly, as reported | Adults with type 2 diabetes on diet and exercise alone (REIMAGINE 1) (n = 189) | 40 weeks | PubMed 42251860Quoted from the sourceonce-weekly subcutaneous cagrilintide 2·4 mg plus semaglutide 2·4 mg (cagrilintide-semaglutide [2·4 mg each]), placebo 2·4 mg plus 2·4 mg, cagrilintide 1·0 mg plus semaglutide 1·0 mg |
| 2.4 mg of each or 1.0 mg of each, with semaglutide and cagrilintide armsSubcutaneous, Once weekly, as reported | Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor, BMI of 25 or more (REIMAGINE 2) (n = 2713) | 68 weeks | PubMed 42251859Quoted from the sourcecagrilintide 2·4 mg plus semaglutide 2·4 mg (hereafter cagrilintide-semaglutide [2·4 mg each]), semaglutide 2·4 mg, cagrilintide 2·4 mg, cagrilintide 1·0 mg plus semaglutide 1·0 mg |
| 2.4 mg of each or 1.0 mg of eachSubcutaneous, Once weekly, as reported | Adults with type 2 diabetes on stable basal insulin, with or without metformin (REIMAGINE 3) (n = 274) | 40 weeks | PubMed 42251856Quoted from the sourceonce per week subcutaneous cagrilintide 2·4 mg plus semaglutide 2·4 mg (hereafter cagrilintide-semaglutide [2·4 mg each]) or cagrilintide 1·0 mg plus semaglutide 1·0 mg |
These rows describe what a study, registration or label reports. They are not recommendations and not instructions, and a figure from one population does not carry over to another.
Safety signals & UK regulatory context
Frequently asked questions
Has CagriSema been approved?
How does the CagriSema evidence differ from semaglutide alone?
Why is an amylin analogue added to semaglutide?
Has CagriSema been compared with tirzepatide?
References
Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.
- Enebo LB, Berthelsen KK, Kankam M, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet (London, England). 2021;397(10286) :1736-1748 doi:10.1016/S0140-6736(21)00845-X · PMID: 33894838
- Lau DCW, Erichsen L, Francisco AM, et al.. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England). 2021;398(10317) :2160-2172 doi:10.1016/S0140-6736(21)01751-7 · PMID: 34798060
- Frias JP, Deenadayalan S, Erichsen L, et al.. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England). 2023;402(10403) :720-730 doi:10.1016/S0140-6736(23)01163-7 · PMID: 37364590
- Garvey WT, Blüher M, Osorto Contreras CK, et al.. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2025;393(7) :635-647 doi:10.1056/NEJMoa2502081 · PMID: 40544433
- Davies MJ, Bajaj HS, Broholm C, et al.. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine. 2025;393(7) :648-659 doi:10.1056/NEJMoa2502082 · PMID: 40544432
- Verma S, Böttcher M, Brown P, et al.. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension (Dallas, Tex. : 1979). 2026;83(2) :e26055 doi:10.1161/HYPERTENSIONAHA.125.26055 · PMID: 41328546
- Yamauchi T, Becker NP, Hagemann CA, et al.. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. The lancet. Diabetes & endocrinology. 2026;14(6) :450-462 doi:10.1016/S2213-8587(25)00402-4 · PMID: 42009015
- Aroda VR, Buzzetti R, Dalskov SM, et al.. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. The lancet. Diabetes & endocrinology. 2026;14(8) :649-661 doi:10.1016/S2213-8587(26)00126-9 · PMID: 42251860
- Buse JB, Bajaj HS, Dalskov SM, et al.. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. The lancet. Diabetes & endocrinology. 2026;14(8) :662-677 doi:10.1016/S2213-8587(26)00125-7 · PMID: 42251859
- Rosenstock J, Billings LK, Gajria R, et al.. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet (London, England). 2026;408(10549) :38-51 doi:10.1016/S0140-6736(26)01022-6 · PMID: 42251856
- Hamarsheh S, Jaber AR, Abu-Khazneh O, et al.. Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. Endocrinology, diabetes & metabolism. 2026;9(4) :e70248 doi:10.1002/edm2.70248 · PMID: 42207966
- Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: an unsourced dose-step table was removed; claims about REDEFINE 2 (placebo comparison only) and nausea against semaglutide alone were corrected; Wegovy label warnings and the REDEFINE 5 result were added; legal statements were replaced with a standard note.
If you spot an error or have new evidence to suggest, please use our corrections policy.
Continue reading
MOTS-c + AOD-9604 — Research Evidence Review: Mitochondrial & Lipolytic Mechanisms
Evidence review of MOTS-c and AOD-9604: what has been studied in animals and in people, what is unknown, and the fact that no study has tested them together.
Tesamorelin + AOD-9604 — Research Evidence Review: Visceral Adipose Research Context
Tesamorelin and AOD-9604 for visceral fat: tesamorelin's label and trials, AOD-9604's rodent, rabbit and manufacturer-linked human work, and no study of the pair.
Tirzepatide + Retatrutide + AOD-9604 — Research Evidence Review: Incretin & Lipolytic Mechanisms
Evidence review of tirzepatide, retatrutide and AOD-9604: label doses, trial results, boxed warning, and the absence of any study of the three together.
Semaglutide — GLP-1 Receptor Agonist (Research Evidence Summary)
Semaglutide is a GLP-1 receptor agonist sold as Wegovy, Ozempic and Rybelsus. Label doses and limits, trial results, the thyroid boxed warning and other risks.
Cagrilintide — Long-Acting Amylin Analogue (Research Evidence Summary)
Cagrilintide is a once-weekly amylin analogue from Novo Nordisk. Trials of cagrilintide alone and with semaglutide (CagriSema), doses studied, risks and unknowns.
Tirzepatide vs Cagrilintide — Incretin vs Amylin Approach to Weight Reduction
Tirzepatide (GIP/GLP-1 agonist, on the MHRA list of licensed GLP-1 medicines) compared with cagrilintide (amylin analogue, investigational): trials, risks and what has not been compared.
Triple Incretin Agonism — Retatrutide and the GLP-1 / GIP / Glucagon Evidence Base
Critical research-literacy review of the GLP-1 / GIP / glucagon triple-agonist class — receptor pharmacology, Phase II and III trial evidence for retatrutide, comparison with tirzepatide, and the UK regulatory framing.